Tularik Strengthens Management Team with Appointment of Andrew J. Perlman, M.D., Ph.D.
Monday October 28, 5:00 am ET
Perlman to Present at the Salomon Smith Barney 2002 Health Care Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 28, 2002--Tularik Inc. (Nasdaq:TLRK - News) today announced that Andrew J. Perlman, M.D., Ph.D., has rejoined the company as executive vice president. Dr. Perlman will resume his leadership role in the Company's strategic planning and communications efforts, as well as play a key role in business development, clinical, regulatory affairs and product commercialization activities.
Dr. Perlman was a member of Tularik's management team for nearly 10 years, serving initially as vice president of medical research and corporate development and later as executive vice president. During the last decade, he played a significant role in Tularik's evolution from a research-stage start-up to a company with multiple drugs in the clinic moving toward commercialization. He returns to Tularik from privately held Affymax, where he served as chief executive officer.
"We have always valued Andy's strategic insights and communication skills as well as his in-depth knowledge of all aspects of our business," said David V. Goeddel, Ph.D., CEO of Tularik. "We are delighted with his decision to return to Tularik."
Dr. Perlman added, "The ability of Tularik to apply innovative techniques of molecular biology, biochemistry and chemistry to understand the causes of disease is of unquestionable value. This expertise allows the Company to select targets and discover novel drugs in a way that improves the probability of success. I have great confidence in our future and our ability to bring important new drugs to market and I am excited to be back on the team."
The Company also announced that Dr. Perlman would present at the Salomon Smith Barney 2002 Global Health Care Conference at The Plaza Hotel in New York, New York today, October 28, 2002 beginning at 11:15 a.m. Eastern Standard Time.
Tularik's presentation will be webcast live and may be accessed at the URL veracast.com. A replay of the presentation will be available for 30 days.
About Tularik
Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has three drug candidates in clinical trials. T67 is moving into a pivotal Phase 2/3 study for the treatment of Hepatocellular Carcinoma (HCC) and T607 is in four Phase 2 trials for the treatment of HCC, non-Hodgkin's lymphoma, ovarian cancer and gastric cancer. T487, for the treatment of inflammatory diseases, is in a Phase 1 trial to evaluate safety. For more information, visit Tularik's Internet website at www.tularik.com.
biz.yahoo.com |
